ArticleTranslational cancer research2026

Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast cancer.

Marcelo Antonini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.